Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c

Outlook Therapeutics (NASDAQ: OTLK) reported Q3 EPS of ($0.09). Revenue for the quarter came in at $9 thousand.

For earnings history and earnings-related data on Outlook Therapeutics (OTLK) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Reddit to join S&P 500 index on Aug. 18, shares leap
• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy